Review: taking Mirapex and Vyvanse together


Summary

Drug interactions are reported among people who take Mirapex and Vyvanse together. This review analyzes the effectiveness and drug interactions between Mirapex and Vyvanse. It is created by eHealthMe based on reports of 30 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Mirapex

Mirapex has active ingredients of pramipexole dihydrochloride. It is often used in restless leg syndrome. (latest outcomes from Mirapex 13,040 users)

Vyvanse

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Vyvanse 12,816 users)

On Sep, 15, 2016

30 people who take Mirapex, Vyvanse are studied.


Number of reports submitted per year:

Mirapex and Vyvanse drug interactions.

Drug effectiveness over time:

Mirapex:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Vyvanse:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 75.0% - (3 of 4 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Mirapex:
  • female: 85.0% - (6 of 7 people)
  • male: 0.0% - (0 of 0 people)
Vyvanse:
  • female: 42.0% - (3 of 7 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Mirapex:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 100.0% - (3 of 3 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 100.0% - (2 of 2 people)
Vyvanse:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 66.0% - (2 of 3 people)
  • 50-59: 50.0% - (1 of 2 people)
  • 60+: 0.0% - (0 of 2 people)

Most common drug interactions over time *:

< 1 month:
  • feeling abnormal
  • insomnia
  • logorrhoea
  • restlessness
  • tremor
1 - 6 months:
  • anorexia
  • dizziness postural
  • nausea and vomiting
  • activities of daily living impaired
  • middle insomnia
  • sleep disorder
6 - 12 months:
  • attention deficit/hyperactivity disorder
  • obsessive-compulsive disorder
1 - 2 years:
  • attention deficit/hyperactivity disorder
  • obsessive-compulsive disorder
2 - 5 years:
  • chills
  • fever
  • headache
  • sinusitis
  • throat - sore
  • cough
not specified:
  • tendonitis
  • abdominal pain upper
  • compartment syndrome
  • dehydration
  • malaise
  • nausea
  • peroneal nerve palsy
  • rectal ulcer
  • mobility decreased
  • nerve compression

Most common drug interactions by gender *:

female:
  • malaise
  • nausea
  • peroneal nerve palsy
  • rectal ulcer
  • headache
  • mobility decreased
  • tendonitis
  • abdominal pain upper
  • compartment syndrome
  • dehydration
male:
  • cataract
  • contusion
  • fall
  • hyporeflexia
  • retinal detachment
  • sleep apnoea syndrome

Most common drug interactions by age *:

10-19:
  • headache
  • insomnia
20-29:
  • abdominal pain upper
  • compartment syndrome
  • dehydration
  • malaise
  • nausea
  • peroneal nerve palsy
  • rectal ulcer
  • tendonitis
  • mobility decreased
  • nerve compression
40-49:
  • attention deficit/hyperactivity disorder
  • contusion
  • fall
  • hyporeflexia
  • obsessive-compulsive disorder
  • sleep apnoea syndrome
50-59:
  • chills
  • fever
  • headache
  • sinusitis
  • throat - sore
  • cough
  • anorexia
  • atrioventricular block second degree
  • blood pressure decreased
  • bradycardia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Mirapex and Vyvanse?

Can you answer these questions?

More questions for: Mirapex, Vyvanse

You may be interested in these reviews

More reviews for: Mirapex, Vyvanse

On eHealthMe, Mirapex (pramipexole dihydrochloride) is often used to treat restless leg syndrome. Vyvanse (lisdexamfetamine dimesylate) is often used to treat attention deficit hyperactivity disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.